Ventricular Assist Device: An Advanced Surgical Intervention for the Treatment of End Stage Heart Failure Laura Coyle, MSN, ACNP-BC VAD Coordinator Advocate.

Slides:



Advertisements
Similar presentations
Advance Heart Failure Therapy
Advertisements

Ventricular Assist Device Exit Site Care
Community Preparation for Caring for Mechanical Circulatory Device Patients University of Wisconsin Hospital And Clinics Ventricular Assist Device Program.
Advanced Heart Failure and the Role of Mechanical Circulatory Support
Left Ventricular Assist Devices “LVAD”
BACKGROUND Ventricular assist devices (VADs) are a proven therapy as bridge-to-cardiac transplantation in Class IIIB and Class IV heart failure patients.
BACKGROUND Ventricular assist devices (VADs) are a proven therapy as bridge-to-cardiac transplantation in Class IIIB and Class IV heart failure patients.
Update on Indications for Cardiac Resynchronization Therapy Maria Rosa Costanzo, M.D., F.A.C.C., F.A.H.A. Medical Director, Midwest Heart Specialists-Advocate.
Purpose To determine whether metoprolol controlled/extended release
Monica Colvin-Adams, MD Assistant Professor of Medicine Advanced Heart Failure and Transplantation University of Minnesota Compassionate Allowances Outreach.
Topics Zoll LifeVest  What it is  Who it treats  How does EMS handle these patients?
Equipoise Does Not Exist for REVIVE IT Andrew Boyle, MD Heart and Vascular Center Director, Florida Chairman of Cardiology Medical Director of Heart Failure,
Heart Failure: Living with a Hurting Heart. Congestive Heart Failure Heart (or cardiac) failure is the state in which the heart is unable to pump blood.
© 2000 Heart Failure Society of America, Inc.
The Heart and Heart Failure in the Year 2013 Jonathan D. Rich, MD Associate Director, Mechanical Circulatory Support Program Bluhm Cardiovascular Institute.
Case Studies Advanced Heart Failure and the Role of Mechanical Circulatory Support Megan Shifrin, RN, MSN, ACNP-BC Vanderbilt University.
Left Ventricular Assist Devices: The What and the Who Lance E. Sullenberger MD FACC FACP Capital Cardiology Associates.
Community Preparation for Caring for Mechanical Circulatory Device Patients University of Wisconsin Hospital And Clinics Ventricular Assist Device Program.
Mechanical Circulatory Support for Advanced Heart Failure Speakers: Lynne A Benish, ACNP-BC Mechanical Assist Device Nurse Practitioner, Cardiac Surgery.
Introduction to Ventricular Assist Device (VAD)
JONATHAN MANT, MD; ABDALLAH AL-MOHAMMAD, MD; SHARON SWAIN, BA, PHD; AND PHILIPPE LARAMEE,DC,MSC, FOR THE GUIDELINE DEVELOPMENT GROUP CHRIS FONTIMAYOR MS-III.
Heart Failure Ben Starnes MD FACC Interventional Cardiology
CHARM-Alternative: Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity - Alternative Purpose To determine whether the angiotensin.
Supporting Patients with CHF Care Transformation Collaborative of R.I. MAUREEN CLAFLIN, MSN, RN. NCM UNIVERSITY MEDICINE GOVERNOR STREET PRIMARY CARE CENTER.
2009 Focused Update: ACCF/AHA Guidelines for the Diagnosis and Management of Heart Failure in Adults p.o.box zip code Done by: Dr.Amin Zagzoog.
Heart Failure: From Failure to Success
9/5/20151 Ventricular Assist Device (VAD) Patients in the Community Liz Amerman, RN, BSN IU Health Methodist VAD Program Manager April 18, 2012.
Treatment of Heart Failure: Beyond Medical Therapy
Risk Assessment and Comparative Effectiveness of Left Ventricular Assist Device and Medical Management in Ambulatory Heart Failure Patients Assessment.
May 2005 EP Show The EP Show COMPANION and CARE-HF Eric Prystowsky MD Director, Clinical Electrophysiology Laboratory St Vincent Hospital Indianapolis,
HeartWare HVAD: Risk Factors for Adverse Outcomes Mark S. Slaughter, MD Professor and Chair Department Cardiovascular and Thoracic Surgery University of.
Medical Progress: Heart Failure. Primary Targets of Treatment in Heart Failure. Treatment options for patients with heart failure affect the pathophysiological.
Community Preparation for Caring for Mechanical Circulatory Device Patients University of Wisconsin Hospital And Clinics Ventricular Assist Device Program.
S. HUNT Tenth International Symposium HEART FAILURE & Co. CARDIOLOGY SCIENCE UPDATE FEMALE DOCTORS SPEAKING ON FEMALE DISEASES Milano aprile 2010.
RALES: Randomized Aldactone Evaluation Study Purpose To determine whether the aldosterone antagonist spironolactone reduces mortality in patients with.
To know more visit HeartFailure.com © 2015 Novartis Pharma AG, May 2015, GLCM/HTF/0028 HEART FAILURE MORTALITY STATISTICS.
Nursing and heart failure
Global Cardiac Assist Devices Market Share, Global Trends, Analysis, Research, Report, Opportunities, Segmentation and Forecast,
Ventricular Assist Devices A Ventricular assist device, or VAD, is a mechanical circulatory device that is used to partially or completely replace the.
Heart failure: The national burden AHA. Heart disease and stroke statistics–2005 update. Koelling TM et al. Am Heart J. 2004;147:74-8. VBWG Affects 1 million.
Professor Davor Miličić, MD, PhD, FESC MECHANICAL SUPPORT TO THE FAILING HEART Department of Cardiovascular Medicine, Zagreb University School of Medicine,
Pediatric Mechanical Circulatory Support (MCS) Ivan Wilmot, MD Heart Failure, Transplant, MCS Assistant Professor The Heart Institute Cincinnati Children’s.
Clinical Review AbioCor® Implantable Replacement Heart H Julie Swain M.D. Cardiovascular Surgeon Ileana Piña M.D. Heart Failure Cardiologist DRAFT.
Ventricular Assist Device: Intervals for dressing changes By. Megan Giska.
Heart Failure Devices: Staying Connected Lisa D. Rathman, MSN, CRNP, CCRN, CHFN The Heart Group of Lancaster General Health Lancaster, PA.
COMET: Carvedilol Or Metoprolol European Trial Purpose To compare the effects of carvedilol (a β 1 -, β 2 - and α 1 -receptor blocker) and short-acting.
Natural History of Heart Failure
Differences in Pulsatile vs. Continuous-Flow Left Ventricular Assist Devices on Renal Function Antone Tatooles, MD; Laura A. Coyle, MSN, ACNP-BC; Colleen.
PHARMACOLOGIC THERAPY  Standard First-Line Therapies Angiotensin-Converting Enzyme Inhibitors (ACEI) β Blockers Diuretics Digoxin  Second line Therapies.
Date of download: 6/3/2016 Copyright © The American College of Cardiology. All rights reserved. From: Risk Assessment and Comparative Effectiveness of.
Ten Year Outcome of Coronary Artery Bypass Graft Surgery Versus Medical Therapy in Patients with Ischemic Cardiomyopathy Results of the Surgical Treatment.
Date of download: 7/9/2016 Copyright © The American College of Cardiology. All rights reserved. From: Results of the Destination Therapy Post-Food and.
These slides highlight a presentation at the Late Breaking Trial Session of the American College of Cardiology 52nd Annual Scientific Sessions in Chicago,
University of Chicago Medicine
Ventricular Assist Device
Mechanical circulatory support
Αντιμετώπιση καρδιακής ανεπάρκειας προχωρημένου και τελικού σταδίου
Fifth INTERMACS annual report: Risk factor analysis from more than 6,000 mechanical circulatory support patients  James K. Kirklin, MD, David C. Naftel,
University of Wisconsin Hospital And Clinics
INOVATE-HF Trial design: Patients with heart failure (HF) were randomized to device implant for vagus nerve stimulation (n = 436) versus optimal medical.
CIBIS II: Cardiac Insufficiency Bisoprolol Study II
Mechanical Circulatory Support Devices HOSEIN PASANDI.
Section III: Neurohormonal strategies in heart failure
Durable Mechanical Circulatory Support in Advanced Heart Failure
Anaerobic threshold responder analysis
Shannon M. Dunlay, MD, MS, Naveen L. Pereira, MD, Sudhir S
MOMENTUM 3 Trial design: Patients with advanced heart failure were randomized to a centrifugal-flow pump (n = 152) vs. an axial-flow pump (n = 142). Results.
Presentation transcript:

Ventricular Assist Device: An Advanced Surgical Intervention for the Treatment of End Stage Heart Failure Laura Coyle, MSN, ACNP-BC VAD Coordinator Advocate Christ Medical Center

Impact of Heart Failure with an Aging Population 5+ million Americans* Nearly 700,000 new cases per year* More than 280,000 patients die of heart failure in the US each year* - 2 nd highest mortality at one year with optimal medical management

Impact of Heart Failure with an Aging Population Nearly 250,000 patients are considered at high risk for repeated hospitalizations -More than 1 million hospitalized for worsening heart failure at a cost of nearly 35 billion* - 20% of hospitalizations are persons over 65* Currently 100,000 patients have advanced end-stage heart failure characterized by: - frequent hospitalizations - reduced quality of life - a complex therapeutic regimen, and a high mortality rate+ *Rosamond W, Flegal K, Furie K, et al. Heart Disease and stroke statistics 2008 update: a report from the American Heart Association Statistics Committee and Stoke Statistics Subcommittee. Circulation. 2008: 117(4): American Heart Association. Heart Disease and Stroke Statistics: 2007 Update. Dallas, Texas:

Progression of Heart Failure

I IIIIIIV 1 10 NYHA CLASS Annual Survival Rate Hospitalizations / year.1.1 Deceased Adapted from Bristow, MR Management of Heart Failure, Heart Disease: A Textbook of Cardiovascular Medicine, 6th edition, ed. Braunwald et al. Class III n 25% of HF Patients n Frequent hospitalizations n Worsening symptoms despite drug therapy n Significant opportunity for new therapies Survival Rate Hospitalizations Natural History of Heart Failure

Treatment Options for Advanced Heart Failure Optimal Medical Therapy Beta Blockers, ACE Inhibitors, ARBs, Aldosterone Antagonists, Diuretic Therapy, Oral Nitrates and Hydralazine, etc. Electrophysiologic Testing and the Use of Devices in Heart Failure - Prophylactic ICD Placement -Biventricular Resynchronization Pacing 2009 Focused Update: ACCF/AHA Guidelines for the Diagnosis and Management of hEart Failure in Adults. J. Am. Coll. Cardiol. Published March 26, 2009

Advanced Surgical Interventions for End- Stage Heart Failure Cardiac Transplantation “gold standard” -Severely limited by shortage of donors; only 2,163 heart transplants in 2008 in US* Ventricular Assist Device for Bridge to Transplant or Destination Therapy for patients ineligible for heart transplantation. United States Department of Health and Human Services. Accessed April 23,

What is a Ventricular Assist Device? A ventricular assist device (VAD) is an implantable device designed to partially replace the function of the failing heart, restoring circulation of blood flow to the body through mechanical circulatory support. VADs are designed to assist either the right (RVAD) or left (LVAD) ventricle, or both at once (BiVAD). Which of these types is used depends primarily on the underlying heart disease and the pulmonary arterial resistance that determines the load on the right ventricle

Advanced Surgical Interventions for End- Stage Heart Failure Use of Left Ventricular Assist Devices - Bridge to Decision - Bridge to Recovery - Bridge to Transplant - Permanent Use for “Destination Therapy ” Non Study Device Implants

REMATCH Trail Multi-Center Randomized Controlled Study designed for patients in Class IV (NYHA) end stage heart failure who did not qualify for a heart transplant. 68 patients randomized to XVE HeartMate LVAD 61 patients randomized to optimal medical therapy

REMATCH Conclusion DT 51% 1-year survival in the LVAD group 27% 2-year survival in the LVAD group OMT 28% 1-year survival in the OMT 10% 2-year survival in the OMT

CHF Reunion at One Year OMM Therapy Group VAD Therapy Group 28 Alive 52 Alive

CHF Reunion at Two Years OMM Therapy 8 Alive VAD Therapy 29 Alive

Beginning of Destination Rematch Study Conclusion- Therapy Risk from death from any cause was 48% lower in the LVAD group “Using an LVAD in patients with advanced heart failure improves survival and quality of life. An LVAD is an acceptable alternative therapy in some CHF patients” N Engl J Med 2001; 345: , Nov 15, 2001

Improved survival and quality of life with a LVAD Long JW et al. Long-term Destination Therapy with the HeartMate XVE left Ventricular Assist Device: improved outcomes since the REMATCH study. CHF. 2005;11:

Patient Selection: Who benefits from a VAD? New York Heart Association (NYHA) Functional Class III to IV or Refractory Heart Failure Left Ventricular Ejection Fraction ≤ 25% Peak VO2 < 14 ml/kg/min Severe HF symptoms despite optimal medical therapy Inability to tolerate medical therapy Requiring inotropes Do not respond to biventricular pacing One or more heart failure related hospital admissions in past 6 months Ineligible for cardiac transplantation

Ventricular Assist Devices Provide mechanical circulatory support to restore the circulation of blood flow to the body. Decreases preload Decreases cardiac workload Increases systemic circulation & tissue perfusion Decreases neurohormonal response Indications for Use Bridge to Decision/ Postcardiotomy/Failure to wean from Bypass Bridge to Recovery Bridge to Transplant Permanent Use for “Destination Therapy”

Ventricular Assist Devices A VAD runs on electrical power 24 hours a day 365 days of the year. Patients may connect to a power base unit to provide consistent power or connect to a set of batteries which must be changed every few hours (varies per device) to maintain a reliable power source. Patients must be connected to power at ALL times.

Ventricular Assist Devices There are several many different VADs. All VADs have the following four parts: An inflow cannula which takes blood from the ventricular to the pump A pump An outflow cannula that takes the pumped blood to the ascending aorta A power source for the pump

Types of Ventricular Assist Devices: Pulsatile vs. Continuous Flow Pulsatile VADs – mimic the natural pulsing action of the heart using positive displacement Device Specific – preload/volume dependent Continuous Flow – normally use either a centrifugal pump or an axial flow pump Device Specific – HVAD vs. HM II LVAD

Indications for Use:Pulsatile vs. Continuous Flow Pulsatile Devices PVAD IVAD Heartmate XVE LVAD Continuous Flow Heartmate II LVAD Heartware HVAD FDA Approved Devices for Bridge to Transplant PVAD/IVAD Heartmate XVE LVAD Heartmate II LVAD Heartware HVAD (currently undergoing clinical trials) FDA Approved Device for Destination Therapy Heartmate XVE LVAD Heartmate II LVAD (pending FDA approval )

IVAD PVAD

Biventricular Support

Portable TLC-II Driver

TLC-II ® Portable VAD Driver

Mode Button Scroll Button Alarm Silence Button Message Display External Power Light VAD Full Lights Change Batt. A Light Battery A Battery B Change Batt. B Light External Power Computer Input Key Switch Pneumatic Connections Full Signal Inputs Normal Alarm Urgent Alarm Battery Clip TLC-II ® Interface and Control Panel

Heartmate XVE Heartmate II

Components of a Ventricular Assist Device

Carry On Components of a Ventricular Assist Device Power Base Unit System Display Module All Batteries Emergency Power Pack Back-up System Controller/Driver Battery Module Battery Clips Battery Holster/Pocket Pack Cell Phone Daily Driveline Dressing Supplies Emergency Contact Information *Total Weight 72.5 lbs

Components of a Ventricular Assist Device

Heartware HVAD

HeartWare ® System Peripherals IN THE HOSPITAL AT HOME HeartWare™ Controller with LCD display, audible alarms and 30 day data storage HeartWare™ Monitor with pump parameters & flow waveforms HeartWare™ Batteries & Charger: 2 Li-ION batteries last up to 12 hours

SO why want a Ventricular Assist Device? IMPROVED Survival - Improved end organ function -Reduced hospitalizations for HF IMPROVED Quality Of Life - Return to normal activities of daily living -Live independently -Drive -Work -Travel

What They Look Like CHF Infusion Clinic Patient VAD Referral in ICU

Enjoying a Ride on his Motorcycle

Distance Traveled

Patient vacationing in San Juan, Puerto Rico

Patient in Puerto Rico following instruction to avoid bathes, swimming pools, and oceans

Patient enjoying the streets of Madrid, Spain

Patient sightseeing in Seattle, Washington

Patient visiting New Orleans, Louisiana